Dr John Campbell reviews Pfizer's new drug and compares it to Ivermectin.
New Pfizer antiviral and ivermectin, a pharmacodynamic analysis New Pfizer antiviral, is designed to block the activity of the SARS-CoV-2-3CL protease, https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate
So, what is a protease? So what is a protease inhibitor? And, what is 3CL? Chymotrypsin-like protease (3CL main protease, or 3CL Mpro)
Identification of SARS-CoV‑2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening (3rd September 2020) https://pubs.acs.org/doi/abs/10.1021/acsptsci.0c00108#
The activity of the anti-SARS-CoV-2 viral infection was confirmed in 7 of 23 compounds Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection https://pubs.rsc.org/en/content/articlehtml/2021/cp/d1cp02967c the strength and persistency of the interaction between IVE and the binding site of 3CLpro indicate that a partial inhibition of the catalytic activity could have place as the drug interacts with the main subdomains that define the enzyme binding pocket:
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents https://www.nature.com/articles/s42003-020-01577-x as shown in Fig. 4, out of 13 OTDs only ivermectin completely blocked ( more than 80%) the 3CLpro activity at 50 µM concentration.
Seems you entered wrong password click here to enter password again.
